CVC Acquires Therakos Business from Mallinckrodt for $925M

Novartis Acquires Anthos Therapeutics for Up to $3.1B

February 11, 2025

Pharmaceuticals

Blackstone Life Sciences and Anthos Therapeutics announced that Novartis will acquire Anthos for up to $3.1 billion, including a $925 million upfront payment to Anthos shareholders. The deal is expected to close in the first half of 2025, subject to customary closing conditions and regulatory approvals. Novartis later completed the acquisition, valuing the transaction at up to $3.1 billion with the $925 million upfront payment.

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

October 10, 2025

Pharmaceuticals

Akero Therapeutics announced it has entered into a definitive agreement to be acquired by Novo Nordisk A/S in a transaction valued at up to $5.2 billion in cash. Under the terms of the deal, Akero shareholders will receive $54.00 per share at closing plus a non-transferable Contingent Value Right (CVR) that could pay an additional $6.00 per share contingent on full U.S. regulatory approval of efruxifermin (EFX) for compensated cirrhosis associated with MASH.

CVC Invests KRW 200 Billion in PharmaResearch to Accelerate Global Expansion

September 5, 2024

Pharmaceuticals

Global private equity firm CVC invested KRW 200 billion in South Korea's PharmaResearch via redeemable convertible preferred shares (RCPS). The minority growth investment will support PharmaResearch’s overseas market entry, strategic M&A activity, and R&D/product pipeline expansion in aesthetic injectables and regenerative medicines.

Partners Group Acquires Pharmathen from BC Partners

July 19, 2021

Pharmaceuticals

Partners Group has agreed to acquire Pharmathen, the leading European drug delivery technology and pharmaceutical manufacturing company, from BC Partners in a transaction valued at approximately EUR 1.6 billion. The deal transfers control of Pharmathen to Partners Group (acting on behalf of its clients) and is aimed at supporting the company’s continued growth — including an intensified push into the US market — building on strong R&D and manufacturing capabilities.

Carlyle and PAI Partners Acquire Theramex from CVC Capital Partners

March 28, 2022

Pharmaceuticals

Global private equity firms Carlyle and PAI Partners have agreed to acquire Theramex, a London-based specialty pharmaceuticals company focused on women's health, from CVC Capital Partners VI. The new owners plan to accelerate Theramex's international expansion and broaden its women's health product suite to drive further organic and inorganic growth.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.